703 related articles for article (PubMed ID: 28753826)
21. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
[TBL] [Abstract][Full Text] [Related]
22. Caveolin-1 Expression in Upper Tract Urothelial Carcinoma.
D'Andrea D; Moschini M; Foerster B; Abufaraj M; Margulis V; Karam J; Lotan Y; Raman J; Mathieu R; Rouprêt M; Karakiewicz PI; Briganti A; Haitel A; Shariat SF
Eur Urol Focus; 2019 Jan; 5(1):97-103. PubMed ID: 28753840
[TBL] [Abstract][Full Text] [Related]
23. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
Sonpavde G; Pond GR; Mullane S; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
BJU Int; 2017 Apr; 119(4):579-584. PubMed ID: 27700015
[TBL] [Abstract][Full Text] [Related]
24. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma.
Emamekhoo H; Dhillon P; Gopalakrishnan D; Elson P; Stephenson A; Magi-Galluzzi C; McKenney J; Harper H; Haber GP; Kaouk J; Lee B; Fergany A; Berglund R; Gong M; Stein R; Krishnamurthi V; Gilligan T; Ornstein M; Rini B; Garcia J; Grivas P
Clin Genitourin Cancer; 2018 Aug; 16(4):e751-e760. PubMed ID: 29551583
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
27. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma.
Faraj SF; Munari E; Guner G; Taube J; Anders R; Hicks J; Meeker A; Schoenberg M; Bivalacqua T; Drake C; Netto GJ
Urology; 2015 Mar; 85(3):703.e1-6. PubMed ID: 25733301
[TBL] [Abstract][Full Text] [Related]
28. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
Udager AM; Liu TY; Skala SL; Magers MJ; McDaniel AS; Spratt DE; Feng FY; Siddiqui J; Cao X; Fields KL; Morgan TM; Palapattu GS; Weizer AZ; Chinnaiyan AM; Alva A; Montgomery JS; Tomlins SA; Jiang H; Mehra R
Ann Oncol; 2016 Sep; 27(9):1706-12. PubMed ID: 27217541
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
[TBL] [Abstract][Full Text] [Related]
30. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
[TBL] [Abstract][Full Text] [Related]
31. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update.
Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Gontero P; Van Rhijn BWG; Mostafid AH; Palou J; Shariat SF
Eur Urol; 2018 Jan; 73(1):111-122. PubMed ID: 28867446
[TBL] [Abstract][Full Text] [Related]
32. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
[TBL] [Abstract][Full Text] [Related]
33. Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.
Faiena I; Astrow SH; Elashoff DA; Jain R; Bot A; Chamie K; Belldegrun AS; Pantuck AJ; Drakaki A
Cancer Immunol Immunother; 2019 May; 68(5):743-751. PubMed ID: 30790015
[TBL] [Abstract][Full Text] [Related]
34. Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study.
Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Bayani J; Bartlett J; Xu B; Downes MR
J Clin Pathol; 2021 Jan; 74(1):53-57. PubMed ID: 32471889
[TBL] [Abstract][Full Text] [Related]
35. An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability.
Lee KS; Choi E; Cho SI; Park S; Ryu J; Puche AV; Ma M; Park J; Jung W; Ro J; Kim S; Park G; Song S; Ock CY; Choe G; Park JH
Histopathology; 2024 Mar; ():. PubMed ID: 38477366
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological significance of the overexpression of MUC1 in upper tract urothelial carcinoma and possible application as a diagnostic marker.
Kobayashi G; Hayashi T; Sentani K; Takemoto K; Sekino Y; Uraoka N; Hanamoto M; Nose H; Teishima J; Arihiro K; Hinata N; Oue N
Pathol Int; 2022 Dec; 72(12):606-616. PubMed ID: 36169278
[TBL] [Abstract][Full Text] [Related]
37. Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection.
Espiritu PN; Sverrisson EF; Sexton WJ; Pow-Sang JM; Poch MA; Dhillon J; Spiess PE
Urol Oncol; 2014 Jul; 32(5):619-24. PubMed ID: 24495448
[TBL] [Abstract][Full Text] [Related]
38. Impact of gender on tumor stage and survival of upper urinary tract urothelial cancer : A population-based study.
Mohamad Al-Ali B; Madersbacher S; Zielonke N; Schauer I; Waldhoer T; Haidinger G
Wien Klin Wochenschr; 2017 Jun; 129(11-12):385-390. PubMed ID: 27670858
[TBL] [Abstract][Full Text] [Related]
39. Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.
Zajac M; Boothman AM; Ben Y; Gupta A; Jin X; Mistry A; Sabalos C; Nielsen A; Manriquez G; Barker C; Antal J; Wang P; Patil P; Schechter N; Rebelatto MC; Walker J
Arch Pathol Lab Med; 2019 Jun; 143(6):722-731. PubMed ID: 30457897
[TBL] [Abstract][Full Text] [Related]
40. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma.
Munari E; Fujita K; Faraj S; Chaux A; Gonzalez-Roibon N; Hicks J; Meeker A; Nonomura N; Netto GJ
Hum Pathol; 2013 Dec; 44(12):2668-76. PubMed ID: 24074531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
